ViaCyte announces two-year data from ViaCyte’s STEP ONE clinical trial
ViaCyte announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01™ (PEC-Encap™) Product Candidate in Type One Diabetes clinical trial. The results indicate the PEC-Encap product candidate has to date been safe and well tolerated. June 23, 2018